Suven Life Science

Jump to

Buy Suven Life Science; target of Rs 315: Dolat Capital

Dolat Capital is bullish on Suven Life Science has recommended buy rating on the stock with a target price of Rs 315 in its research report dated February 07, 2019.
Suven Life gets 4 patents; keen to enter Japan market

Suven Life Science has received patents for four of its new chemical entities (NCEs) in China, Mexico and New Zealand and the company also plans to very soon enter Japan market which is considered as next big opportunity for generic drug makers.
Suven Life gets three patent approvals for CNS molecules

Drug firm Suven Life Sciences today said it has received three product patents for CNS molecules, two from Eurasia and one from Canada, which could be used for treating various central nervous system disorders.
Suven gets 4 product patents for several key markets

Suven Life Science Monday said it has got product patent for its new chemical entity, 5-HT compounds used to treat neurodegenerative diseases like Parkinson and Schizophrenia from Europe, New Zealand, Australia and Korea.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Suven Life Science

Buy Suven Life Science; target of Rs 315: Dolat Capital

Suven Life gets 4 patents; keen to enter Japan market

Suven Life gets three patent approvals for CNS molecules

Suven gets 4 product patents for several key markets